12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ONO-4538: Phase I started

Innate Pharma S.A. (Euronext:IPH, Marseille, France) said Bristol-Myers began an open-label, U.S. Phase I trial to evaluate 0.1-3 mg/kg doses of BMS-986015 in combination with 3 mg/kg BMS-936558 in about 150 patients with advanced solid tumors. Under an...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >